Phase I Clinical Trial of Recombinant Human Endostatin Administered as a Short Intravenous Infusion Repeated Daily
Joseph P. Eder(Yale Cancer Center), Donald Küfe(Dana-Farber Cancer Institute), Rocio García‐Carbonero(Research Institute Hospital 12 de Octubre), Mary T. Keogan(Royal College of Surgeons in Ireland), JoAnn Proper(Dana-Farber Cancer Institute), Carolyn Sidor(Dana-Farber Cancer Institute), Thomas A. Puchalski(Dana-Farber Cancer Institute), David P. Ryan(East Carolina University), Barbara P. Rattner(University of California San Diego), Eric Phillips(Dana-Farber Cancer Institute), Jeffrey W. Clark(Massachusetts General Hospital), Judah Folkman(Boston Children's Hospital), Jeffrey G. Supko(Harvard University), William E. Fogler(Dana-Farber Cancer Institute), Milos J. Janicek(Dana-Farber Cancer Institute), Lowell E. Schnipper(Fox Chase Cancer Center), Susan L. Connors(Dana-Farber Cancer Institute), Lawrence N. Shulman(National Center for Health Research), Moira Kirvan(Dana-Farber Cancer Institute), Nancy M. Kinchla(Dana-Farber Cancer Institute)
Cited by 244
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Angiogenesis.
|Journal of Biological Chemistry|1992|2.7k
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
|Nature|2014|2.4k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k